|Expense Ratio (net)||0.73%|
|Last Cap Gain||0.00|
|Morningstar Risk Rating||High|
|Beta (3Y Monthly)||1.60|
|5y Average Return||N/A|
|Average for Category||N/A|
|Inception Date||Dec 16, 1985|
A burgeoning economy and steady influx of funds make conditions ripe for diversification and further strengthening of the capital base.
Broadly encouraging economic conditions, favorable tax policies and a higher number of approvals from the FDA makes healthcare mutual funds a hotbed of money
The decline in biotech stocks is momentary and we expect the industry to bounce back in the coming days. So consider investing in these three biotech mutual funds.
Broadly encouraging economic conditions, favorable policies and a higher number of approvals from the FDA makes healthcare mutual funds a hotbed of money.